$TARA
Protara Therapeutics, Inc.

2018 Q3 Form 10-Q Financial Statement

#000117184318007677 Filed on November 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.270M $1.970M
YoY Change 15.23% -15.09%
% of Gross Profit
Research & Development $2.354M $10.34M
YoY Change -77.23% 113.47%
% of Gross Profit
Depreciation & Amortization $22.00K $40.00K
YoY Change -45.0% 0.0%
% of Gross Profit
Operating Expenses $4.622M $12.31M
YoY Change -62.44% 71.73%
Operating Profit -$4.622M -$12.31M
YoY Change -62.44% 71.73%
Interest Expense $110.0K $80.00K
YoY Change 37.5% 60.0%
% of Operating Profit
Other Income/Expense, Net $112.0K -$1.000K
YoY Change -11300.0% -101.69%
Pretax Income -$4.510M -$12.31M
YoY Change -63.36% 73.14%
Income Tax
% Of Pretax Income
Net Earnings -$4.510M -$12.31M
YoY Change -63.35% 73.17%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$10.02M -$27.98M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.20M $47.40M
YoY Change -44.73% 0.85%
Cash & Equivalents $18.23M $19.99M
Short-Term Investments $8.000M $27.40M
Other Short-Term Assets $900.0K $600.0K
YoY Change 50.0% -64.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $27.08M $47.98M
YoY Change -43.56% -1.52%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $280.0K
YoY Change -28.57% -29.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $300.0K
YoY Change -66.67% 8.7%
Total Long-Term Assets $322.0K $580.0K
YoY Change -44.48% -13.69%
TOTAL ASSETS
Total Short-Term Assets $27.08M $47.98M
Total Long-Term Assets $322.0K $580.0K
Total Assets $27.41M $48.56M
YoY Change -43.57% -1.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $385.0K $226.0K
YoY Change 70.35% -61.76%
Accrued Expenses $2.149M $8.868M
YoY Change -75.77% 111.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.534M $9.094M
YoY Change -72.14% 84.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.534M $9.094M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.534M $9.094M
YoY Change -72.14% 84.01%
SHAREHOLDERS EQUITY
Retained Earnings -$205.2M -$184.2M
YoY Change 11.41% 20.53%
Common Stock $19.00K $18.00K
YoY Change 5.56% 5.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.87M $39.47M
YoY Change
Total Liabilities & Shareholders Equity $27.41M $48.56M
YoY Change -43.57% -1.68%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$4.510M -$12.31M
YoY Change -63.35% 73.17%
Depreciation, Depletion And Amortization $22.00K $40.00K
YoY Change -45.0% 0.0%
Cash From Operating Activities -$3.120M -$5.920M
YoY Change -47.3% -10.98%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K
YoY Change -100.0% -83.33%
Acquisitions
YoY Change
Other Investing Activities $6.010M -$14.08M
YoY Change -142.68% 1556.47%
Cash From Investing Activities $6.000M -$14.10M
YoY Change -142.55% 1466.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.860M 21.54M
YoY Change -86.72% 107600.0%
NET CHANGE
Cash From Operating Activities -3.120M -5.920M
Cash From Investing Activities 6.000M -14.10M
Cash From Financing Activities 2.860M 21.54M
Net Change In Cash 5.740M 1.520M
YoY Change 277.63% -120.19%
FREE CASH FLOW
Cash From Operating Activities -$3.120M -$5.920M
Capital Expenditures $0.00 -$10.00K
Free Cash Flow -$3.120M -$5.910M
YoY Change -47.21% -10.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
prto Foreign Currency Remeasurement Gain Loss
ForeignCurrencyRemeasurementGainLoss
25000
prto Foreign Currency Remeasurement Gain Loss
ForeignCurrencyRemeasurementGainLoss
-196000
prto Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
2853000
prto Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
1287000
prto Proceeds From Issuance Of Common Stock Under Espp
ProceedsFromIssuanceOfCommonStockUnderESPP
84000
prto Proceeds From Issuance Of Common Stock Under Espp
ProceedsFromIssuanceOfCommonStockUnderESPP
58000
prto Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs
ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
prto Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs
ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
21536000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
385000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
291000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
35000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2149000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8949000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208536000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
202953000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
904000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
747000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2647000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2459000
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26736643
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24831151
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26736643
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24831151
CY2018Q3 us-gaap Assets
Assets
27405000
CY2017Q4 us-gaap Assets
Assets
43979000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
27083000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
43480000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
21497000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
32633000
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
7989000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
20991000
CY2018Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
7987000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12307000
CY2018Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2018Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
20000
CY2018Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
7987000
CY2017Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
20971000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18225000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21170000
CY2018Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
26200000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21192000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36414000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18247000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20008000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2945000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16406000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
20971000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
27291765
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25877695
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19221292
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17674729
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19221292
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17674729
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
19000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
18000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4507000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15452000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24420000
us-gaap Depreciation
Depreciation
83000
us-gaap Depreciation
Depreciation
115000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.82
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-196000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2268000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1970000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6802000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6299000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6706000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4015000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
73000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-589000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1049000
CY2018Q3 us-gaap Investment Income Net
InvestmentIncomeNet
113000
CY2017Q3 us-gaap Investment Income Net
InvestmentIncomeNet
83000
us-gaap Investment Income Net
InvestmentIncomeNet
311000
us-gaap Investment Income Net
InvestmentIncomeNet
161000
CY2018Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
22000
CY2017Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
22000
CY2018Q3 us-gaap Liabilities
Liabilities
2534000
CY2017Q4 us-gaap Liabilities
Liabilities
9240000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27405000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43979000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2534000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9240000
CY2018Q3 us-gaap Loans Pledged As Collateral
LoansPledgedAsCollateral
22000
CY2017Q4 us-gaap Loans Pledged As Collateral
LoansPledgedAsCollateral
22000
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; border-collapse: collapse; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 23px; text-align: justify"><div style="display: inline; font-size: 10pt; color: Black"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div></td> <td style="width: 8px"><div style="display: inline; color: Black">&nbsp;</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt; color: Black"><div style="display: inline; font-weight: bold;">Organization and Operations</div></div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; color: Black"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; color: Black"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; color: Black"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; color: Black">Proteon Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a late-stage biopharmaceutical company focused on the development of novel, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease. The Company was formed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2001 </div>and incorporated on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 24, 2006.</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 29.7pt; margin: 0pt 0"><div style="display: inline; color: Black">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; color: Black">The Company devotes substantially all of its efforts to product research and development, initial market development and raising capital. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> generated any product revenue related to its primary business purpose to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, competition from other companies, the need for development of commercially viable products and the need to obtain adequate additional financing to fund the development of its product candidates. The Company is also subject to a number of risks similar to other companies in the biotechnology industry, including regulatory approval of products, uncertainty of market acceptance of products, competition from therapeutic alternatives and larger companies, compliance with government regulations, protection of proprietary technology, dependence on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties and product liability.</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 29.7pt; margin: 0pt 0"><div style="display: inline; color: Black">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; color: Black">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>the Company had cash, cash equivalents and available-for-sale investments of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$26.2</div> million. The Company believes that its existing cash, cash equivalents and available-for-sale investments will be sufficient to fund operations and capital expenditures into the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> The Company had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$205.2</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018.</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 16.65pt; margin: 0pt 0"><div style="display: inline; color: Black">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; color: Black">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 12, 2015, </div>the Company filed a shelf registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> (the &#x201c;Registration Statement&#x201d;), and entered into a Sales Agreement with Cowen and Company, LLC (the &#x201c;Sales Agreement&#x201d;) to establish an at-the-market (&#x201c;ATM&#x201d;) equity offering program pursuant to which Cowen are able, with the Company&#x2019;s authorization, to offer and sell up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$40</div> million of the Company&#x2019;s Common Stock at prevailing market prices from time to time. The Registration Statement became effective on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 12, 2016. </div>The Company pays Cowen a commission equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3%</div> of the gross proceeds of the sales price of all shares sold through it as sales agent under the Sales Agreement. The offering costs are offset against proceeds from the sale of common stock under this agreement. The Company filed a prospectus supplement on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 14, 2018 </div>because the Company is currently subject to General Instruction <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">I.B.6</div> of Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> which limits the amounts that the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>sell under the Registration Statement. For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>the Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">896,811</div> shares of Common Stock under the Sales Agreement for aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million offset by total offering costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.1</div> million. For both the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>the Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,494,579</div></div> shares of common stock under the Sales Agreement for aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million. For both the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>total offering costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$46,000</div>,</div> were offset against the proceeds from the sale of common stock. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,494,579</div> shares of common stock sold under the ATM offering program during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>were all sold on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 25, 2018 </div>to New Leaf Venture Partners LLC.</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 29.7pt; margin: 0pt 0"><div style="display: inline; color: Black">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; color: Black">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 22, 2017, </div>the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with a syndicate of current and new institutional investors, led by an affiliate of Deerfield Management Company, L.P., pursuant to which the Company agreed to issue and sell to the investors an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,000</div> shares of the Company&#x2019;s Series A Convertible Preferred Stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share (the &#x201c;Series A Preferred&#x201d;), for a purchase price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> per share, or an aggregate gross purchase price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22.0</div> million, all upon the terms and conditions set forth in the Purchase Agreement (the &#x201c;Series A Financing&#x201d;). The Company closed the Series A Financing on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2, 2017 (</div>see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>).</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; color: Black">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; color: Black">Pursuant to the Series A Financing, on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2, 2017, </div>the Company entered into a registration rights agreement with the holders of the Series A Preferred (the &#x201c;Registration Rights Agreement&#x201d;). On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 3, 2017, </div>in accordance with the Registration Rights Agreement, the Company filed a registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> to register the common stock issuable upon conversion of the Preferred Shares. The registration statement became effective on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 21, 2017.</div></div></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2937000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22990000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13014000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22546000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18920000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16654000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-4510000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-12307000
us-gaap Net Income Loss
NetIncomeLoss
-15470000
us-gaap Net Income Loss
NetIncomeLoss
-24413000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4510000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19054000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15470000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31160000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
112000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
517000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
359000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
4622000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
12306000
us-gaap Operating Expenses
OperatingExpenses
15987000
us-gaap Operating Expenses
OperatingExpenses
24772000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4622000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12306000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15987000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24772000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
276000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
207000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
69000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
100000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
218000
CY2018Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
CY2017Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
19000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-84000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
206000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
198000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
12951000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
31443000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000
CY2018Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
CY2017Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
6747000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
6747000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
871000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1339000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
23990000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8920000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1999000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
109000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
200000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
259000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2354000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10336000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9185000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18473000
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
22000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
22000
CY2018Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
22000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
22000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-205211000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189741000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
13.30
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
121000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
130000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2681072
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4597226
us-gaap Share Based Compensation
ShareBasedCompensation
2647000
us-gaap Share Based Compensation
ShareBasedCompensation
2459000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1946255
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
42013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
83433
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2041600
CY2018Q3 us-gaap Security Deposit
SecurityDeposit
22000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.18
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.12
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
130000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4597226
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.12
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.82
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.61
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
125000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y328D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y292D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y255D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y255D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
24871000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
34739000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17824186
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17574371
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17725095
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17158032

Files In Submission

Name View Source Status
0001171843-18-007677-index-headers.html Edgar Link pending
0001171843-18-007677-index.html Edgar Link pending
0001171843-18-007677.txt Edgar Link pending
0001171843-18-007677-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_110718p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
prto-20180930.xml Edgar Link completed
prto-20180930.xsd Edgar Link pending
prto-20180930_cal.xml Edgar Link unprocessable
prto-20180930_def.xml Edgar Link unprocessable
prto-20180930_lab.xml Edgar Link unprocessable
prto-20180930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending